Evidence map›Paper›PMID 26391471›Full record

SynthesisBMC research notes2015

Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review.

Tam Dang-Tan, Afisi Ismaila, Shiyuan Zhang, Victoria Zarotsky, Mark Bernauer

2 registry-linked trialsAbstract readSystematic Review
In one paragraph

Synthesis in BMC research notes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02750189 completednot on this map

The Economic Burden of Patients With COPD in South Korea

TypeobservationalSponsorKonkuk University Medical CenterRan2015 to 2017Enrolled390ConditionsCOPD, Chronic Obstructive Pulmonary DiseaseArmsDirect cost, Indirect cost
NCT03355677 nacompletednot on this mapstarted 2017, after this paper: background citation

A Clinical Interventional Study Into Airways Disease Case Finding and Complex Case Management

TypeinterventionalSponsorUniversity of SouthamptonRan2017 to 2019Enrolled327ConditionsCOPD, AsthmaArmsCase finding Clinic, At Risk Case Clinics, Usual Care
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. 20-year trends in excess costs of COPD.The European respiratory journal · 2025
    Article
  6. Article
  7. Article
  8. A cross-sectional survey on the effects of ambient temperature and humidity on health outcomes in individuals with chronic respiratory disease.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Towards precision in defining COPD exacerbations.Breathe (Sheffield, England) · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.International journal of chronic obstructive pulmonary disease · 2019
    Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tam Dang-TanGlaxoSmithKline, 7333 Mississauga Road, Mississauga, ON, L5N 6L4, Canada. tam.x.dang-tan@gsk.com.
Afisi IsmailaGlaxoSmithKline, Research Triangle Park, NC, USA. afisi.s.ismaila@gsk.com.
Shiyuan ZhangGlaxoSmithKline, 7333 Mississauga Road, Mississauga, ON, L5N 6L4, Canada. shiyuan.x.zhang@gsk.com.
Victoria ZarotskyOptum, Eden Prairie, MN, USA. vzarotsky@yahoo.com.
Mark BernauerOptum, Eden Prairie, MN, USA. rphberny@att.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a chronic, irreversible disease and a leading cause of worldwide morbidity and mortality. In Canada, COPD is the fourth leading cause of death. This systematic review was undertaken to update healthcare professionals and decision makers regarding the recent clinical, humanistic and economic burden evidence in Canada.

methodsA systematic literature search was conducted in PubMed, EMBASE, and Cochrane databases to identify original research published January 2000 through December 2012 on the burden of COPD in Canada. Each search was conducted using controlled vocabulary and key words, with "COPD" as the main search concept and limited to Canadian studies, written in English and involving human subjects. Selected studies included randomized controlled trials, observational studies and systematic reviews/meta-analyses that reported healthcare resource utilization, quality of life and/or healthcare costs.

resultsOf the 972 articles identified through the literature searches, 70 studies were included in this review. These studies were determined to have an overall good quality based on the quality assessment. COPD patients were found to average 0-4 annual emergency department visits, 0.3-1.5 annual hospital visits, and 0.7-5 annual physician visits. Self-care management was found to lessen the overall risk of emergency department (ED) visits, hospitalization and unscheduled physician visits. Additionally, integrated care decreased the mean number of hospitalizations and telephone support reduced the number of annual physician visits. Overall, 60-68 % of COPD patients were found to be inactive and 60-72 % reported activity restriction. Pain was found to negatively correlate with physical activity while breathing difficulties resulted in an inability to leave home and reduced the ability to handle activities of daily living. Evidence indicated that treating COPD improved patients' overall quality of life. The average total cost per patient ranged between CAN $2444-4391 from a patient perspective to CAN $3910-6693 from a societal perspective. Furthermore, evidence indicated that COPD exacerbations lead to higher costs.

conclusionsThe clinical, humanistic and economic burden of COPD in Canada is substantial. Use of self-care management programs, telephone support, and integrated care may reduce the overall burden to Canadian patients and society.

Indexed as

Cost of IllnessCanadaHumansPulmonary Disease, Chronic Obstructive

Identifiers

PMID26391471
PMCPMC4578756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.